Mirtazapine Zydus

Mirtazapine, the active ingredient in Mirtazapine Zydus, is a tetracyclic antidepressant presented as an oral dosage form for oral administration. It is used to treat major depressive disorder, helping to improve mood, sleep, and appetite in adult patients who require pharmacologic therapy.

GNH USA supplies Mirtazapine Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable logistics for global distribution. The company adheres to stringent quality standards and provides comprehensive documentation to support import and regulatory requirements.

Mirtazapine acts on central neurotransmitter pathways involved in mood regulation, primarily used for depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood. - Treatment‑resistant depression: provides an alternative mechanism when other antidepressants are ineffective. - Depression with insomnia or loss of appetite: helps improve sleep quality and stimulate appetite. - Depressive episodes in bipolar disorder (as adjunct): assists in managing depressive phases when used with mood stabilizers.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or behavior, especially early in therapy - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)

When prescribing mirtazapine, clinicians should consider several precautionary measures to ensure patient safety.

- Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor weight: track changes due to appetite stimulation. - Evaluate for suicidal ideation: especially during the first weeks of treatment. - Use cautiously in the elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper the dose to prevent withdrawal symptoms. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis. - Other serotonergic antidepressants (e.g., SSRIs, SNRIs, TCAs): risk of serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampin): may reduce therapeutic effect. - Antihistamines: combined use can enhance sedative effects. - Alcohol: may potentiate CNS depression.